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Abstract
ELISA is commonly used for the detection of urinary 8-oxo-7,8-dihydro-2'deoxyguanosine (8-oxodG), a marker of whole body oxidative stress. However, the
method has been criticized for high inter-laboratory variability and poor agreement with
chromatographic techniques. We performed an inter-laboratory comparison of 8-oxodG
assessed in 30 urine samples and a urine spiked with four different concentrations of 8oxodG by ELISA using standardized experimental conditions, including: sample pretreatment with solid-phase extraction (SPE), performing analysis using a commercial kit
from a single manufacturer and strict temperature control during the assay. We further
compared the ELISA results with high-performance liquid chromatography-tandem mass
spectrometry (HPLC-MS/MS) and performed tentative identification of compounds that
may contribute to the discrepancy between both methods. For all but one participating
laboratory (Data 1) we observed consistent ELISA results lying mostly within 1 SD of the
mean 8-oxodG concentration. Mean 8-oxodG levels assessed by ELISA correlated with
the data obtained by HPLC-MS/MS (R=0.679, p<0.001). The correlation improved when
Data 1 were excluded from the analysis (R=0.749, p<0.001). In the correlation plot we
identified three outlying urine samples; one with an ELISA 8-oxodG concentration lower,
and two with 8-oxodG levels higher, than those measured by HPLC-MS/MS. Omitting
these samples further improved inter-methodology agreement (R=0.869, p<0.001). In the
outliers with high 8-oxodG estimates various aromatic and heterocyclic compounds were
tentatively identified using gas chromatography-mass spectrometry (GC/MS); application
of authentic standards revealed the presence of saccharides, including D-glucose and Dgalactose as putative interfering substances. In summary, assay standardization improved
ELISA inter-laboratory agreement, although some variability is still observed. While the
assay shows reasonable correlation with HPLC-MS/MS, there are still compounds in urine
2

that affect the anti-8-oxodG antibody binding, contributing to overestimation of 8-oxodG by
ELISA in some samples. Thus, despite significant improvement, ELISA still cannot be
considered a robust alternative to the chromatographic techniques.
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Introduction
Oxidative stress, resulting from the imbalance between levels of antioxidants and
oxidants in the organism, in favor of the latter, represents a major source of damage to
macromolecules [1]. Although DNA oxidation causes the formation of a number of oxidized
products [2], 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) is the most abundant and
most commonly studied oxidized deoxynucleotide [3]. This compound may be measured in
blood, saliva, urine or other biological matrices [4]. However, due to the availability of urine
and high stability of 8-oxodG in this matrix [5], urinary levels of 8-oxodG have become a
popular biomarker of whole body oxidative stress [6]. Although several methods of 8oxodG detection have been developed, they may be generally categorized into
chromatographic and immunochemical approaches [4,7]. Chromatographic techniques,
particularly high-performance liquid chromatography-tandem mass spectrometry (HPLCMS/MS), are considered the gold standard methods of urinary 8-oxodG detection.
However, for many laboratories obtaining and running expensive chromatographic
instrumentation is not feasible. Therefore, antibody-based techniques (mostly competitive
ELISA) are widely used despite their potential shortcomings stemming from non-specific
interactions of antibodies with compounds in the urine [3].
The complex nature of urine, which consists of many chemicals including inorganic
salts, urea, various organic compounds and organic ammonium salts [8], is main challenge
to urinary analyzes of 8-oxodG. These compounds may interfere with analytical
procedures, particularly with antibody-based methods. To overcome this potential source
of analytical bias, solid-phase extraction (SPE)-based protocols are sometimes used for
sample pre-treatment [9–11]. It has been shown that the SPE pre-treament significantly
improves the quality of ELISA data [9,11]. Over the years, several comparisons of 8oxodG levels analyzed by chromatography and ELISA have been made [7,11–20]. The
4

agreement between the methods ranged from no correlation (r=0.14, p=0.95) [15] to
almost perfect agreement (r=0.98, p<0.001) [17]. However, despite reasonable
correlations observed in some studies, most of the authors reported several-fold higher 8oxodG concentrations estimated by ELISA than those measured by chromatography.
A recent inter-laboratory and between-technique comparison of urinary 8-oxodG
analyzes organized by the European Standards Committee on Urinary (DNA) Lesion
Analysis (ESCULA) revealed that not only there is poor agreement between the data
obtained by ELISA and chromatography, but also high inter-laboratory variability for those
study participants that used ELISA [7,20]. The studies concluded that ELISA variability is
greater than the variability of chromatographic methods and that ELISA cannot be used to
determine absolute levels of 8-oxodG. Moreover, high inter-laboratory ELISA variability
currently prevents the method from being used for pool data from multiple labs for
subsequent analysis.
In the present study we took advantage of ELISA improvements described previously
[11,16] to conduct the inter-laboratory comparison of 8-oxodG analysis in 30 urine samples
and a urine spiked with four concentrations of 8-oxodG. The main aim of our work was to
verify whether application of a common ELISA protocol would help to decrease the interlaboratory variability so that it is comparable with that observed for chromatographic
techniques. We obtained data from five participating laboratories. All participants used a
commercial ELISA kit from a single manufacturer and adhered strictly to the common
protocol that included the pre-treatment of urine using SPE and incubation of the purified
samples with the primary antibody at 4 °C. We further compared the obtained data with
HPLC-MS/MS analysis and identified samples for which there was a greater disagreement
between the methods. In these samples we aimed to identify compounds that might
contribute to the discrepancy.
5

Materials and Methods
Samples collection
Spot urine samples were obtained from 30 non-smoking pregnant women (aged 21-38
y) in Hospital Ceske Budejovice, Czech Republic. These subjects participated in another
study focused on the effect of environmental pollution on the health of mothers and their
newborns. All subjects gave signed informed consent and could cancel their participation
at anytime. The study was approved by the Ethical Committee of the Institute of
Experimental Medicine in Prague.
Urine samples were frozen at -20 °C immediately after collection and stored at -80 °C
after delivery to the Institute of Experiment Medicine. Before analysis in individual
laboratories, the samples were thawed and aliquoted. A urine sample obtained from a
healthy male individual (age 43) was spiked with 8-oxodG to reach the final concentration
of the compound of 0.25; 0.5; 1.0 and 2.5 ng/mL. The samples were coded; the code was
not known to persons performing the assay. The samples were then shipped on dry ice to
the study participants.

Pre-treatment of the samples and ELISA
Before analysis, the samples were thawed and centrifuged for 10 min at 13,000 g. The
supernatants were used for further analysis. Solid-phase extraction was performed as
previously described [10] with modifications introduced in [11]. For SPE, 250 µL of urine
was diluted to 1 mL with HPLC water. After purification and drying under a stream of
nitrogen, the samples were reconstituted in 250 µL PBS, prior to addittion to the ELISA
plate.
For ELISA, the Highly Sensitive 8-OHdG Check kit (JaICA, Shizuoka, Japan) was
used. The samples were analyzed in triplicate, 50 µL sample/well, according to the
6

manufacturer’s instructions. The instructions included omitting the outer plate wells and
incubation of the samples with the primary antibody at 4 °C overnight. The results were
expressed in ng/mL, but for further analyzes they were normalized per creatinine content
(nmol 8-oxodG/mmol creatinine).
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HPLC-MS/MS analysis

Creatinine assay
The analysis of creatinine was performed by the Jaffe picric acid method [21]
individually in each participating laboratory. The inter-laboratory variability was very low;
coefficient of variation (CV) was around 5%. The samples were analyzed in duplicate;
creatinine concentrations were expressed in mmol/L.

Profiling organic compounds in selected urine samples using GC/MS and HPLC-MS/MS
The preparation of samples was identical as for ELISA, with the exception of the
solvent used to dissolve the SPE eluate (methanol instead of PBS). For the analysis, 1 µL
of the eluate was used; for the identification of saccharides, 50 µL of the eluate was
transformed to trimethylsilyl derivatives before the analysis. GC separation was performed
on a fused silica SLB-5ms capillary column (30 m x 0.20 mm x 0.20 µm; Sigma-Aldrich, St.
Louis, MO, USA) with helium as the carrier gas. A Saturn 2100T ion trap mass
spectrometer (Varian, Walnut Creek, CA, USA), which operated in electron ionization and
full scan mode at an electron ionization energy of 70 eV, was used for the detection of the
unknown substances in urine samples. Tentative identification of unknown selected
compounds was performed by comparing of their mass spectra with the spectra of the
NIST (The National Institute of Standards and Technology) library.
7
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The same samples (1 µL of the eluate dissolved in methanol) were also analyzed by
HPLC-MS/MS a TripleQuad 6410 triple quadrupole mass spectrometer (Agilent, Santa
Clara, CA, USA) equipped with an electrospray ion source (ESI), an Agilent 1200 Binary
Pump System with an autosampler and a MassHunter software system. The ionization of
the analytes was performed in the positive ion mode and full scan detection. The
separation of compounds was achieved on a reverse-phase mode using a Supelcosil LCPAH HPLC column (150 mm x 3 mm, 5 μm; Supelco, Bellefonte, PA, USA).

Statistical analysis
First, inter-laboratory variability of 8-oxodG concentrations determined by ELISA was
tested using ANOVA; the differences between individual laboratories were analyzed using
Tukey post-hoc test. Then, mean ELISA 8-oxodG values and SD were calculated and
compared with 8-oxodG concentrations from the HPLC-MS/MS analysis by paired t-tests.
Agreement between the participating laboratories and between techniques was assessed
by Pearson correlations and Bland-Altman plots. All calculations were performed using
SPSS IBM 20 (Chicago, IL, USA).

Results
The samples were analyzed in five laboratories (Lab 1-Lab 5) from which six sets of
ELISA data (Data 1-Data 6) and one set of HPLC-MS/MS results were obtained. In one
laboratory (Lab 5), the ELISA of the urine samples, but not the samples spiked with 8oxodG, was performed by two persons independent of each other thus generating to sets
of data (Data 5 and Data 6). The laboratory responsible for HPLC-MS/MS also conducted
ELISA (Lab 4, Data 4). The ELISA results were pooled and analyzed separately for the
urine sample spiked with 8-oxodG and for unspiked urine.
8

Analysis of 8-oxodG in the urine sample spiked with 8-oxodG
We first analyzed the ability of ELISA to distinguish between urine samples spiked with
increasing concentrations of 8-oxodG. The results showed consistent data for all
participating laboratories with the exception of Lab 1 (Data 1; Fig. 1A, Table 1). This
laboratory detected higher 8-oxodG levels in all tested samples, the estimated
concentrations laying outside the SD error bars. This resulted in CV ranging from 23.8% to
47.2% and significant differences of 8-oxodG concentrations between participants
detected by ANOVA (p=0.013). Excluding Data 1 from the analyzes significantly
decreased the inter-laboratory variability, although we still observed some samples (those
analyzed by Lab 4, Data 4) exceeding the SD interval (Fig. 1B). Also the CV decreased to
the range of 13.7% - 19.6% and no significant difference was found between the
laboratories (p=0.675) (Table 1). The mean ELISA values showed the concentration trend
of 8-oxodG, although it was not detected by all laboratories particularly for samples with
low 8-oxodG levels. Comparison of ELISA results with HPLC-MS/MS showed that,
unexpectedly, 8-oxodG concentrations measured by chromatography were about 60%
higher than those detected by ELISA (Table 1). The difference between the methods was
statistically significant (p<0.001), although there was a good correlation between both data
sets (R=0.982, p=0.003 and R=0.990, p=0.001 for ELISA data both including and
excluding Data 1, respectively; Fig. 2A and 2B). The level of agreement between ELISA
and HPLC-MS/MS results was assessed using Bland-Altman plots (Fig. 2C and 2D). The
plots show the mean value of the two measurements plotted against the difference
between these values. They confirmed lower 8-oxodG estimates by ELISA but otherwise
reasonable agreement between the methods. The agreement further improved after Data
1 were excluded from the analysis.

9

Analysis of 8-oxodG in unspiked urine samples
We further analyzed the inter-laboratory variability of 8-oxodG levels in selected 30
urine samples. The results demonstrate mostly consistent data across all samples,
although we observed some outliers (Fig. 3). The greatest departure from the mean values
was found for the results obtained by Lab 1, for which 50% samples lay outside the SD
interval. The outliers were also found among data from other participants, particularly Lab
4, although the deviation from the mean value was less pronounced. The CV of 8-oxodG
concentrations calculated for individual samples ranged from 10.6% to 53.8%, with the
mean CV value of 26.6%. Excluding Data 1 from the analysis significantly decreased the
variability, resulting in the CV ranging between 8.6% and 29.0% (the mean CV value of
17.6%). This approach, however, emphasized the outliers among Data 4 and changed the
rank order (Fig. 4). The ELISA data obtained in individual laboratories correlated mostly
well, with the R value exceeding 0.8 in all but one case (p<0.001; Table 2). The exception
was, however, Data 1, for which the R value ranged from 0.337 to 0.752 with one nonsignificant result (Table 2). The ELISA results from individual laboratories significantly
correlated with the HPLC-MS/MS data (R ranging from 0.606 to 0.781, p<0.001), again
with the exception of Data 1 for which the correlation was poor and non-significant (Table
2).
The between-technique comparison identified a significant correlation between the
mean ELISA and HPLC-MS/MS data (R=0.679, p<0.001; Fig. 5A). Although the correlation
was significant, we observed three notable outliers: one sample with 8-oxodG
concentration identified by the ELISA as being lower than that by the chromatography
(sample 18) and two samples with ELISA 8-oxodG estimates higher than by HPLC-MS/MS
(samples 20, 21; the three outliers circled in red in Fig. 5B). Excluding Data 1 improved the
correlation (R=0.749, p<0.001; Fig. 5B), but the outliers were still present. Again, the
10

ELISA underestimated 8-oxodG concentrations, although the disagreement was less
obvious as can be seen in Bland-Altman plots (Fig. 5B and 5D). The plots also showed the
three outliers mentioned before. For all of them, the disagreement exceeded the
confidence limits for bias of 2SD.
To see how the results would change if the three outliers were not present, we
calculated correlations and prepared Bland-Altman plot after excluding these samples from
the analysis. The correlation between the ELISA and the HPLC-MS/MS data further
improved (R=0.869, p<0.001; Fig. 6A), as did the between-technique agreement. The
ELISA still underestimated 8-oxodG levels (the difference analyzed by the paired t-test
being significant, p<0.001), although the interval for confidence limits for bias was
narrower (Fig. 6B).

Profiling organic compounds in the ELISA outliers
The discrepancy between the methods observed for the three outlying samples did not
seem to be primarily driven by non-consistent data generated by the ELISA in individual
laboratories. Although some samples lay outside the SD interval in the inter-laboratory
comparison (Fig. 4), the CV was acceptable (12.9; 15.8 and 24.2%, for sample 20, 18 and
21, respectively) and the ELISA data from all laboratories were consistently higher (for
samples 20, 21) or lower (for sample 18) than the chromatography results. Thus, we
assumed that the lack of agreement is method-specific, probably associated with specific
compounds causing cross-reactivity of the primary antibody used in ELISA. To elucidate
potential differences in chemical composition of the urine, we performed GC-MS and
HPLC-MS/MS analyzes of the outlying samples and compared them with the sample for
which 8-oxodG concentration was comparable using both methods (sample 13, denoted
further as the control sample).
11

The GC-MS allows detection of volatile non-polar and moderately polar compounds as
well as their quantification and tentative identification. The chromatograms of the samples
20 and 21 (higher 8-oxodG concentrations by ELISA) were characterized by a number of
peaks that were not present in the chromatogram of the control sample 13 (Fig. 7A, 7B,
7D). On the other hand, the number of peaks in sample 18 was lower than in the control
sample 13 (Fig. 7C and 7D). Most of the compounds tentatively identified based on the
chromatograms contained aromatic or heterocyclic rings (Table 3). The sum of their
concentrations was greatest for sample 21 for which the highest disagreement between
the methods was observed (2.33-fold difference in 8-oxodG concentration between ELISA
and HPLC-MS/MS).
Detection of saccharides by the GC-MS based on the application of authentic
standards revealed a similar trend with the highest concentration sum observed for
sample 21. In this sample we identified almost 26-fold higher concentration of beta-Dgalactose and almost 30-fold higher concentration of beta-D-glucose than in the control
sample 13 (Table 4).
For profiling the organic compounds not detectable by the GC-MS we used the HPLCMS/MS. Although this method did not allow tentative identification of the compounds in the
eluates, we found different peak profiles in the individual samples. This was particularly
true for sample 20 and 21 when compared with the control sample 13 In these two
samples we observed extra peaks not detected in samples 13 and 18 suggesting the
presence of compounds possibly interfering with 8-oxodG detection by ELISA (Fig. 8).

Discussion
Due to the relative simplicity, speed and low cost of the laboratory equipment and
chemicals, ELISA is considered an attractive alternative to the chromatographic methods
12
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for detection of 8-oxodG in urine samples. However, there is a concern regarding the
specificity of the anti-8-oxodG antibodies presently available and thus the agreement
between the ELISA and chromatography data. Moreover, ELISA seems to be prone to
higher inter-laboratory variability than chromatography [7,20] which currently disqualifies
the method from application in large, multicenter studies and/or meta-analyzes. Several
attempts have been made to improve ELISA-chromatography agreement while analyzing
urinary 8-oxodG levels. They included HPLC pre-purification of urine before ELISA [13],
incubation of the primary antibody with the samples at lower temperature (4 °C) [16] and
application of urease to remove urea that has been shown to cross-react with the primary
antibody [17]. However, to the best of our knowledge, our study is the first one to address
the issue of substantial inter-laboratory variability previously observed for ELISA. Also, for
the first time, the SPE pre-treament together with the standardized protocol was tested on
a larger sample set with the aim to improve ELISA-chromatography agreement.
As the clone of anti-8-oxodG antibody and the ELISA format (commercial kit vs. inhouse assay) have been shown to significantly impact the results [7,11], we opted for the
commercial ELISA kit provided by a single manufacturer (Highly Sensitive 8-OHdG Check
kit; JaICA, Shizuoka, Japan) to be used by all participating laboratories. Moreover, the
urine samples were processed and the ELISA performed using a standardized protocol
that has been shown to give best results when compared with the HPLC-MS/MS [11]. This
included samples pre-purification by SPE previously advocated for HPLC-MS/MS
application [10] and incubation of the samples with the primary antibody at 4 °C overnight,
an approach tested by Evans et al. [16] and now recommended by the kit manufacturer.
The results were corrected to creatinine levels as we have shown that creatinine crossreacts with the anti-8-oxodG antibody and creatinine normalization improves betweentechnique correlation [11]. One of the participating laboratories further analyzed 8-oxodG
13

levels by HPLC-MS/MS. The data were then tested for inter-laboratory agreement and the
mean ELISA 8-oxodG levels were compared with the HPLC-MS/MS data to check for
between-technique variability.
Even though the standardized ELISA protocol was used, one of the participating
laboratories delivered results that in many cases were not in agreement with other ELISA
data and that exhibited poor correlation with both other ELISA results and HPLC-MS/MS
data. Despite our efforts we were not able to identify the source of disagreement for these
data. To exclude the impact of potential (although not proven) experimental issues, we
presented our data both with and without the outlying ELISA results. Excluding these
results helped to improve both inter-laboratory and between-technique correlation and
agreement, particularly for the urine sample spiked with different 8-oxodG concentrations.
For this sample we observed concentration-dependent increase of 8-oxodG and good
correlation and agreement with the HPLC-MS/MS data, although the chromatography
detected lower 8-oxodG levels than the ELISA. This result was unexpected as most of the
previous studies comparing these techniques proved that the ELISA overestimated 8oxodG concentrations, probably due to the non-specific interaction of the primary antibody
with the urine compounds [7,12–15,17–22]. However, in another study, the ELISA
underestimated 8-oxodG levels after incubation of the samples with the primary antibody
at 4 °C, although this difference was not statistically significant [16].
Excluding the outlying Data 1 from the analysis of unspiked urine samples improved
inter-laboratory variability, although we still observed the samples exceeding the SD
interval. Overall, the correlation between the ELISA data from individual laboratories was
statistically significant with correlation coefficient mostly above 0.8. The correlation
between ELISA and HPLC-MS/MS was also significant, but correlation coefficients were
lower. In the correlation and Bland-Altman plots we detected three notable outliers which
14

significantly contributed to the discrepancy between both sets of data. Omitting them
further improved the data agreement bringing the correlation coefficient to R=0.869 and
narrowing confidence limits for bias in Bland-Altman plot. While two of these outliers
exhibited higher 8-oxodG estimates by the ELISA, the third sample had more than 40%
higher 8-oxodG concentration detected by the HPLC-MS/MS.
As the three outliers were clearly the samples causing most of the between-technique
disagreement (after omitting Data 1), we attempted to characterize the profile of organic
compounds by GC-MS and HPLC-MS/MS. This combined approach allowed us to detect
compounds with various chemical properties, taking advantage of public databases to
tentatively identify GC-MS detected peaks and authentic standards to identify selected
mono- and disaccharides. The two samples with higher ELISA 8-oxodG estimates
exhibited a number of compounds either not present in the control sample 13, or present
at very low concentrations. This suggests that 8-oxodG overestimation is caused by the
cross-reactivity of the antibody with these (and possibly other) compounds that remained
in the urine despite the SPE pre-treatment. Although the identification is tentative, we can
broadly classify them as aromatic and heterocyclic compounds, e.g. compounds
containing structures similar to 8-oxoguanine in 8-oxodG. Furthermore, authentic
standards allowed identification of several monosaccharides, from which concentrations of
beta-D-galactose and alpha- and beta-D-glucose in two ELISA outliers (samples 20 and
21) several fold exceeded those in the control sample 13. The structures of these
compounds are partially similar to 2'-deoxy-D-ribose in 8-oxodG. Moreover, it has been
reported that the epitope of the primary antibody spans from the hydroxyl group on C8 of
guanine to the 2'-deoxyribose backbone [23], making the cross-reactivity of the antibody
with the above-mentioned monosaccharides likely. It should be mentioned that although
the concentrations of these monosaccharides were relatively high compared to the control
15
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sample 13, they were within a lower interval of the physiological range for healthy subjects
reported in the literature [24]. This implies that provided that the two monosaccharides
contribute to the cross-reactivity of the primary antibody, urine samples from any person
may yield false-positive 8-oxodG concentrations. However, we should point out that our
experiments did not conclusively prove the cross-reactivity of the primary antibody with the
compounds detected in the chromatograms. To do that, we would have to use the
compounds suspected from the cross-reactivity as competitors in the ELISA and check the
levels of antibody binding inhibition. This was, however, out of the scope of our present
study but points to the direction of future work. Some such tests have been done
previously for several nucleosides, urea, creatine and creatinine with no cross-reactivity
detected [23], although later studies found cross-reactivity with urea [17] and creatinine
[11]. While the effect of these compounds can be eliminated by SPE or normalization per
creatinine levels, there are probably many other urine components that affect the ELISA 8oxodG assessment and the effect of which cannot be removed by the above-mentioned
approaches.
The third outlier contained lower 8-oxodG concentration than the control sample 13.
This result is difficult to explain by the simple cross-reactivity of the primary antibody with
urine components. Evans et al. speculated that other high molecular weight compounds in
urine, dissimilar to 8-oxodG (proteins, saccharides), may also contribute to ELISA vs.
HPLC-MS/MS disagreement [16]. As the 8-oxodG ELISA has a competitive format, we
suggest that such compounds could possibly physically block the binding of the primary
antibody to the antigen in the sample thus facilitating the interaction of the antibody with
the antigen immobilized to the bottom of the wells thus decreasing the estimate of 8oxodG in the urine. However, if true, these compounds are hypothetical as they were not
detected in any of the chromatograms.
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The data presented in our manuscript indicate that: (1) Inter-laboratory comparison of
the ELISA results is possible, although with some reservations. The fact that we were not
able to identify the reason for discrepancy observed particularly for Data 1 is worrying and
suggests that under certain circumstances the method may not generate reproducible
results. For inter-laboratory analyzes this may be relatively easily overcome by
administration of a urine sample to all study participants that would serve as a common
standard. Subsequently, the data from the laboratories that showed discrepancies in the
concentrations of these standards would be excluded. (2) The agreement between 8oxodG ELISA and HPLC-MS/MS can be significantly improved by approaches described
previously, specifically urine pre-treatment by SPE [11] and incubation of the primary
antibody with the samples at 4 °C [16]. However, even these steps do not guarantee a
perfect agreement between the techniques, as (yet to be identified) compound(s) in some
urine samples may interfere with the antibody binding and cause falsely high or low 8oxodG estimates. This fact particularly complicates a routine application of ELISA for 8oxodG analysis, as currently there is no way to identify the outliers without running HPLCMS/MS analysis alongside ELISA. However, this would eliminate any advantage of ELISA
as a fast, easy and relatively inexpensive method.
Although it is a known fact that there exists a discrepancy between ELISA and
chromatography and the latest study describing the steps that would improve betweentechnique agreement was published two years ago [11], new papers still appear that do
not take the necessary improvement steps into account. Out of 17 human studies
published between 2013 and 2015 that we found in the PubMed database using keywords
“8-oxodG” or “8-OHdG” “urine” and “ELISA” and for which we were able to retrieve full-text,
only one acknowledged improvement of ELISA by the incubation of primary antibody at 4
°C [25] and none of them used the SPE pre-treatment step. Furthermore, we found two
17
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studies that described development of new methods for 8-oxodG detection in urine [26,27].
The authors of both studies validated the new methods by comparing the results with 8oxodG concentrations measured by ELISA kits rather than by the gold standard
chromatographic methods. Moreover, the urine samples were not pre-treated, except for
removal of precipitates by centrifugation and filtration.
In light of the results of our present study, it should be advisable to always combine the
8-oxodG ELISA analysis with the SPE pre-treatement keeping in mind that even these
steps will not guarantee reliable 8-oxodG detection for some samples.

Commented [6]: I wanted to say that before ELISA the
samples should be always SPE pre-treated. But even this
extra step will not guarantee that for some samples the 8oxodG concentrations detected by ELISA will be correct.

Summary

I slightly modified the sentence. Does it make sense now?

In the present study we showed that using a standardized protocol and a commercial

Commented [7]: I agree this should be re-thought. I
changed the text; lets see what other co-authors say...

kit from a single manufacturer led to a good inter-laboratory agreement of 8-oxodG
analysis by ELISA for most of the participating laboratories. However, to eliminate a
laboratory/laboratories generating possibly outlying data, common urine standards should
be distributed along the analyzed samples.
The modified ELISA reported here substantially improved agreement of the method
with HPLC-MS/MS analysis. However, we still detected some samples with 8-oxodG
values that differed from the HPLC-MS/MS data. Because it is impossible to predict such
samples and thus to exclude them from the analysis, we conclude that currently the ELISA
is not suitable as a replacement for chromatographic methods. To achieve that, interfering
substances would have to be identified and pre-purification steps would have to be further
optimized.
It is essential for the scientific community to be aware of advantages of the modified
ELISA and apply the recommended steps that are currently known to improve interlaboratory and between-technique agreement. However, at the same time, the limitations
18

Commented [8]: As I mentioned before I think that extra
steps needed for urine processing may also result in errors,
therefore urine as a common standard might be better…
Creatinine determination might introduce some errors, but in
our study the results were very consistent between labs: the
CV was only around 5%. I mentioned that in the Methods.

of the assay should be considered when planning the experiments to avoid generation of
misleading data. More work is needed to to further improve the quality of the ELISA data.
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Figure Legends
Figure 1. 8-OxodG concentrations in unspiked urine (sample 1) and the urine sample
spiked with known concentrations of 8-oxodG (sample 2-5) analyzed by ELISA in all
participating laboratories (Fig. 1A) and in four laboratories after Data 1 have been
excluded (Fig. 1B). Mean 8-oxodG values (red horizontal sign) and SD (red vertical bars)
are shown.

Commented [9]: Regarding the target 8-oxodG values in
the figure – I was considering it but then I realized that I was
not sure how to do that. The 8-oxodG standard of a known
amount was added to a urine sample with unknown 8-oxodG
concentration. Probably the most precise value we have is
2.58 nmol/mmol (the result of HPLC-MS/MS) but this is
about 50% higher than the mean ELISA results. So, we
would have to use some ELISA data. But which would be
appropriate? The mean value, or the mean value minus Data
1? Well, at this moment I decided against showing the target
value :-)
But if my thoughts are wrong, please correct me...

Figure 2. Correlation and between-technique agreement for 8-oxodG concentrations in
unspiked urine and the urine sample spiked with known concentration of 8-oxodG
measured by ELISA and HPLC-MS/MS. The ELISA data from all participating laboratories
correlated well with chromatography (R=0.982, p=0.003; Fig. 2A); the correlation improved
slightly after Data 1 have been excluded from the analysis (R=0.990, p=0.001; Fig. 2B).
However, Bland-Altman plot showed underestimation of 8-oxodG levels by ELISA (Fig. 2C,
2D). The between-technique agreement improved after Data 1 have been removed from
the analysis (Fig. 2D).
Figure 3. Ranked mean 8-oxodG concentrations and SD in urine samples analyzed by
ELISA in all participating laboratories. Mean 8-oxodG values (red horizontal sign) and SD
(red vertical bars) are shown.
Figure 4. Ranked mean 8-oxodG concentrations and SD in urine samples analyzed by
ELISA in the participating laboratories after excluding Data 1. Mean 8-oxodG values (red
horizontal sign) and SD (red vertical bars) are shown.
Figure 5. Correlation and between-technique agreement for 8-oxodG levels in urine
samples analyzed by ELISA and HPLC-MS/MS. There was a significant correlation
between ELISA data from all participating laboratories and HPLC-MS/MS (R=0.679,
p<0.001; Fig. 5A), that further improved after Data 1 have been excluded from the analysis
(R=0.749, p<0.001; Fig. 5B). Bland-Altman plots showed underestimation of 8-oxodG
20

levels by ELISA and improved agreement after removal of Data 1 from the analysis (Fig.
5C, 5D). There were three notable outliers detected in both correlation and Bland-Altman
plots (samples 18, 20, 21; circled in red in Fig. 5B). Sample 13 (the control sample): near
perfect between-technique agreement has been obtained; the sample was used as a
control in identification of compounds in the outliers (more details in the text and Fig. 7).
Figure 6. Correlation and between-technique agreement for 8-oxodG levels in urine
samples analyzed by ELISA and HPLC-MS/MS after the three outlying samples have been
excluded. The correlation between the data improved (R=0.869, p<0.001; Fig. 6A),
although the difference between the methods was still statistically significant (p<0.001).
The ELISA underestimated 8-oxodG levels, although the between-technique agreement
improved resulting in narrower interval for confidence limits for bias (Fig. 6B).
Figure 7. GC-MS chromatograms and tentative identification of organic compounds in the
urine samples for which the ELISA 8-oxodG levels were substantially higher (sample 20,
Fig. 7A; sample 21, Fig. 7B) and lower (sample 18, Fig. 7C) than those assessed by the
HPLC-MS/MS. In sample 13 comparable 8-oxodG concentrations were obtained by both
methods (Fig. 7D).
Figure 8. HPLC-MS/MS chromatograms of organic compounds in the urine samples for
which the ELISA 8-oxodG levels were substantially higher (sample 20, Fig. 8A; sample 21,
Fig. 8B) and lower (sample 18, Fig. 8C) than those assessed by the chromatography. In
sample 13 comparable 8-oxodG concentrations were obtained by both methods (Fig. 8D).
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Table 1. Creatinine-normalized 8-oxodG levels in unspiked urine and in the urine sample spiked with known concentration of 8-oxodG:
pooled ELISA data from all participating laboratories; the data after excluding the outlying results; the results obtained by HPLC-MS/MS.
Sample (ID)

8-oxodG (ELISA, all data)

8-oxodG (ELISA, excl. Data 1)

HPLC-MS/MS

Mean±SD (nmol/mmol)a

CV (%)

Mean±SD (nmol/mmol)b

CV (%)

8-oxodG (nmol/mmol)

Urine (1)

1.73±0.49

28.5

1.53±0.21

14.0

2.58

Urine + 8-oxodG 0.25 ng/mL (2)

2.16±0.85

39.2

1.75±0.24

14.0

3.08

Urine + 8-oxodG 0.5 ng/mL (3)

2.17±0.73

33.5

1.86±0.26

14.2

3.11

Urine + 8-oxodG 1 ng/mL (4)

2.76±1.31

47.2

2.19±0.30

13.7

3.47

Urine + 8-oxodG 2.5 ng/m (5)

3.65±0.87

23.8

3.36±0.66

19.6

4.67

a

b

p=0.013, results of ANOVA, a comparison of all laboratories running ELISA
p=0.675,

results

of

ANOVA,

a

comparison

of

laboratories
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running

ELISA

after

excluding

Data

1

Table 2. Pearson correlation between 8-oxodG levels in 30 urine samples measured by
ELISA in individual laboratories and by HPLC-MS/MS.

ELISA

ELISA

ELISA

ELISA

ELISA

HPLC-

Data 2

Data 3

Data 4

Data 5

Data 6

MS/MS

ELISA

R=0.543;

R=0.752;

R=0.462;

R=0.514;

R=0.337;

R=0.267;

Data 1

p=0.002

p<0.001

p=0.013

p=0.004

p=0.068

p=0.153

ELISA

R=0.908;

R=0.916;

R=0.917;

R=0.900;

R=0.751;

Data 2

p<0.001

p<0.001

p<0.001

p<0.001

p<0.001

ELISA

R=0.888;

R=0.845;

R=0.730;

R=0.606;

Data 3

p<0.001

p<0.001

p<0.001

p<0.001

ELISA

R=0.846;

R=0.837;

R=0.636;

Data 4

p<0.001

p<0.001

p<0.001

ELISA

R=0.887;

R=0.735;

Data 5

p<0.001

p<0.001

ELISA

R=0.781;

Data 6

p<0.001
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Table 3. Tentative identification of abundant compounds in selected urine samples by GC-MS.

Sample ID (concentration, ng/ml)
Compound

18

20

21

13

Benzeneacetic acid, methyl ester

463

24716

30532

1034

2-Methyl-4-propyl-thiazole

6.2

10031

8852

0

Azidotrimethylsilane

0

30251

48094

118

Benzamide

0

560

478

0

Benzeneacetamide

0

10702

14361

0

Benzeneacetic acid

0.5

286

386

0.5

5-Amine_N(Phenylmethyl)-1H-Tetrazole

0

22879

16382

5.3

3,4-Dibenzyloxyphenol

0

1808

2118

65.8

1,3-Diphenyl-2-propanone

0.6

2493

2073

45.8

N-(phenylacetyl)-glycine

0.3

9741

12793

20

25

4-OH-2-Propenoic acid

1.5

449

891

1.4

Pregnane-3,20-diol diacetate (peak 1)

592

1746

2472

1163

Pregnane-3,20-diol diacetate (peak 2)

22.6

86.8

290

102

Table 4. Identification and quantification of saccharides in selected urine samples by GC-MS based on authentic standards. Fold
difference is related to comparison of saccharide concentrations between samples 18, 20, 21 and the control sample 13.

Sample ID (concentration, ng/ml) (fold difference)
Compound

18

20

21

13

alfa-D-Galactose

4.9 (0.02)

11.9 (0.05)

15.5 (0.06)

239

D-Mannose

550 (1.48)

745 (2.00)

444 (1.19)

372

beta-D-Galactose

52.3 (1.29)

75.2 (1.86)

1031 (25.5)

40.5

26

alfa-D-Glucose

56.7 (1.31)

119 (2.75)

1276 (29.5)

43.2

beta-D-Glucose

119 (0.64)

628 (3.36)

1431 (7.67)

187

alfa-Lactose

162 (0.40)

161 (0.40)

306 (0.76)

404

Trehalose

6.5 (1.63)

0.0 (0)

0.0 (0)

4.0

beta-Lactose

112 (0.28)

154 (0.39)

342 (0.86)

396
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